Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya

American Journal of Tropical Medicine and Hygiene

Volumn 90, Issue 1, 2014, Pages 33-39

  Mueller, Yolanda K ^a   Kolaczinski, Jan H ^b   Koech, Timothy ^a   Lokwang, Peter ^a   Riongoita, Mark ^a   Velilla, Elena ^a   Brooker, Simon J ^c   Chappuis, François ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b TUBERCULOSIS AND MALARIA   (Switzerland)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIGEN; K39 ANTIGEN; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AGGLUTINATION TEST; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CHILD; CIRCANNUAL RHYTHM; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; EPIDEMIOLOGICAL DATA; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; INFANT; KENYA; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCHOOL CHILD; PREVALENCE; RAPID DIAGNOSTIC TEST; RAPID TEST; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEASONAL VARIATION; SPLEEN; SPLENOMEGALY; TREATMENT OUTCOME; UGANDA; VERY ELDERLY; VISCERAL LEISHMANIASIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; HUMANS; KENYA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUDAN; UGANDA; YOUNG ADULT;

EID: 84892697293     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.13-0150     Document Type: Article

References (23)

1. World Health Organization, 2010. Control of the Leishmaniases. Report of a meeting of the WHO Expert Committee on Control of Leishmaniases, Geneva, 22-26 March 2010. WHO Technical Report Series; no. 949.
2. Elnaiem DA, 2011. Ecology and control of the sand fly vectors of Leishmania donovani in East Africa, with special emphasis on Phlebotomus orientalis. J Vector Ecol 36: S23-S31.
3. Gebre-Michael T, Malone JB, Balkew M, Ali A, Berhe N, Hailu A, Herzi AA, 2004. Mapping the potential distribution of Phlebotomusmartini and P. orientalis (Diptera: Psychodidae), vectors of kala-azar in East Africa by use of geographic information systems. Acta Trop 90: 73- 86.
4. Jamjoom MB, Ashford RW, Bates PA, Chance ML, Kemp SJ, Watts PC, Noyes HA, 2004. Leishmania donovani is the only cause of visceral leishmaniasis in East Africa; previous descriptions of L. infantum and "L. archibaldi" from this region are a consequence of convergent evolution in the isoenzyme data. Parasitology 129: 399- 409.
5. Fendall NR, 1961. The spread of kala-azar in Kenya. East Afr Med J 38: 417-419.
6. Fendall NR, 1950. Kala-azar in the Kitui Reserve. East Afr Med J 27: 291-296.
7. Fendall NR, McKinnon JA, 1956. Kala-azar in the Baringo District of Kenya; progress report. J Trop Med Hyg 59: 208-212.
8. Mutero CM, Mutinga MJ, Ngindu AM, Kenya PR, Amimo FA, 1992. Visceral leishmaniasis and malaria prevalence in West Pokot District, Kenya. East Afr Med J 69: 3 - 8.
9. Wykoff DE, Barnley GR, Winn MM, 1969. Studies on kala-azar in Uganda-entomological observations. East Afr Med J 46: 204-207.
10. Kager PA, Rees PH, 1983. Splenic aspiration. Review of the literature. Trop Geogr Med 35: 111-124.
11. Mueller Y, Nguimfack A, Cavailler P, Couffignal S, Rwakimari JB, Loutan L, Chappuis F, 2008. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol 102: 11-19.
12. Mueller Y,Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F, 2009. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 14: 910-917.
13. Chappuis F, Mueller Y, Nguimfack A, Rwakimari JB, Couffignal S, Boelaert M, Cavailler P, Loutan L, Piola P, 2005. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 43: 5973-5977.
14. Cunningham J, Hasker E, Das P, el Safi S, Goto H, Mondal D, Mbuchi M, Mukhtar M, Rabello A, Rijal S, Sundar S, Wasunna M, Adams E, Menten J, Peeling R, Boelaert M, 2012. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 55: 1312-1319.
15. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M, 2006. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333: 723.
16. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917-924.
17. Seaman J, Boer C, Wilkinson R, de Jong J, deWilde E, Sondorp E, Davidson R, 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 21: 188-193.
18. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R, 2007. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 101: 19-24.
19. Ritmeijer K, Davidson RN, 2003. Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins Sans Frontieres interventions against kala-azar in the Sudan, 1989- 2003. Trans R Soc Trop Med Hyg 97: 609-613.
20. Veeken H, Ritmeijer K, Seaman J, Davidson R, 2000. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 5: 312-317.
21. Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E, 2010. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 4: e855.
22. Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM, 2000. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 143: 136-143.
23. Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid, AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M, 2012. Sodium stibogluconate (SSG) and paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomized controlled trial. PLoS Negl Trop Dis 6: e1674.